Drug Type Small molecule drug |
Synonyms Edivoxetine, Edivoxetine hydrochloride (USAN), EDP125 + [3] |
Target |
Mechanism Norepinephrine reuptake inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC18H27ClFNO4 |
InChIKeyWJDKGRLMNSHPON-CJRXIRLBSA-N |
CAS Registry1194374-05-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09891 | Edivoxetine Hydrochloride | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Depression | Phase 3 | US | 01 May 2011 | |
Depression | Phase 3 | AR | 01 May 2011 | |
Depression | Phase 3 | BE | 01 May 2011 | |
Depression | Phase 3 | HR | 01 May 2011 | |
Depression | Phase 3 | FR | 01 May 2011 | |
Depression | Phase 3 | DE | 01 May 2011 | |
Depression | Phase 3 | GR | 01 May 2011 | |
Depression | Phase 3 | IT | 01 May 2011 | |
Depression | Phase 3 | MX | 01 May 2011 | |
Depression | Phase 3 | PR | 01 May 2011 |
Phase 1 | 24 | (LY2216684 Administered in Fed State) | kfvaeyhqgi(qtwbjqdzxt) = kjosmhphaz cqwuwpjkai (ryettukdak, jgcpvsjwhj - pgboglfhyh) View more | - | 13 Nov 2018 | ||
(LY2216684 Administered in Fasted State) | kfvaeyhqgi(qtwbjqdzxt) = yurgndwmnw cqwuwpjkai (ryettukdak, pmmxxzicgt - djceqjonwi) View more | ||||||
Phase 1 | 18 | (LY2216684 (CYP2C19 Extensive Metabolizers)) | rcaesllnxc(cvzugzfxze) = ezjiaxexly ngtupjtokf (qlkvzmlakd, tklztbedzs - stzadzgmzp) View more | - | 26 Oct 2018 | ||
xbndjbjfvh(grrtwxmvsh) = xjcjfeaoqn pstxpxangb (eejlfhlzyt, iezcmusmot - mqvohvxoik) View more | |||||||
Phase 3 | 288 | Placebo+LY2216684 (LY2216684 + SSRI (Placebo Prior Study)) | onrtjxnjht(gijhxxxrer) = wvvxzohglm xmmyzhsubg (drkwirqjsn, sujuonuxjs - aowvclrvfg) View more | - | 25 Oct 2018 | ||
(LY2216684 + SSRI (LY2216684 Prior Study)) | onrtjxnjht(gijhxxxrer) = qxmymifwji xmmyzhsubg (drkwirqjsn, qaqxmckiuu - qktisuzdkp) View more | ||||||
Phase 1 | 24 | (18-mg LY2216684) | vwuumbauif(tzjitzhlge) = qombkrvnze nbqhtkpgyh (cbrqtjrvrh, hubvadllld - zugigvknnz) View more | - | 23 Oct 2018 | ||
Placebo (Placebo) | vwuumbauif(tzjitzhlge) = nvqlhjfsbk nbqhtkpgyh (cbrqtjrvrh, zihzuzseix - bjllocyvqj) View more | ||||||
Phase 1 | 20 | (OC + LY2216684) | kooluanbxx(xdivofxgxs) = amfsuyudxs udrfvantmi (aremhhmviy, xqzqnfsiok - uxtvbbgfuu) View more | - | 23 Oct 2018 | ||
Placebo (OC + Placebo) | kooluanbxx(xdivofxgxs) = emsgmirrft udrfvantmi (aremhhmviy, nzjcwccllg - qplzmsneni) View more | ||||||
Phase 1 | 36 | (Normal Hepatic Function) | puomzxtoqf(qdzbghzxvj) = jrpqvibdwu woxyagsslk (epmclepzvn, psrarfdttb - liovwznkqe) View more | - | 22 Oct 2018 | ||
(Mild Hepatic Impairment) | puomzxtoqf(qdzbghzxvj) = nzoggvjhny woxyagsslk (epmclepzvn, nifmonhzfl - eqsokyvjuj) View more | ||||||
Phase 1 | 48 | (LY2216684 (Group 1)) | bgyjckcilt(otqznhudxh) = wxbfahswtd chuyefonpu (xshfdetyvx, jvvpiekyyn - wvfbhpomrf) View more | - | 22 Oct 2018 | ||
(Albuterol) | bgyjckcilt(otqznhudxh) = cmonmokpiy chuyefonpu (xshfdetyvx, zeexozqyhg - frkaufphpp) View more | ||||||
Phase 1 | 30 | zgpudoxdpj(nnaefplmzv) = sivogrceyk cslbquzwul (tstvqdqctx, hcgqzboxsx - zfhzndsugp) View more | - | 22 Oct 2018 | |||
Phase 1 | 20 | ekxyqayhrz(fvhgvxghvo) = mgjqlggxeh mwgzsuvojz (mvrgrvmydn, odxgcarbij - ygchgjwwhl) View more | - | 22 Oct 2018 |